Drugs /

gbr 1302

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for gbr 1302

Gbr 1302 has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating gbr 1302, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for gbr 1302 clinical trials.

Breast carcinoma and malignant solid tumor are the most common diseases being investigated in gbr 1302 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Gbr 1302
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gbr 1302 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gbr-1302, anti-her2/anti-cd3 bispecific monoclonal antibody gbr 1302, anti-her2 x anti-cd3 bispecific monoclonal antibody gbr 1302, isb 1302, gbr1302
Drug Target(s) [2]:
CD3, ERBB2
NCIT ID [1]:
C142889

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.